Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.

Pérez-Belmonte, Luis M; Sanz-Cánovas, Jaime; García de Lucas, María D; Ricci, Michele; Avilés-Bueno, Beatriz; Cobos-Palacios, Lidia; Pérez-Velasco, Miguel A; López-Sampalo, Almudena; Bernal-López, M Rosa; Jansen-Chaparro, Sergio; Miramontes-González, José P; Gómez-Huelgas, Ricardo

Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.

The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure. In this observati...

Descripción completa

Detalles Bibliográficos
Autores:	Pérez-Belmonte, Luis M, Sanz-Cánovas, Jaime, García de Lucas, María D, Ricci, Michele, Avilés-Bueno, Beatriz, Cobos-Palacios, Lidia, Pérez-Velasco, Miguel A, López-Sampalo, Almudena, Bernal-López, M Rosa, Jansen-Chaparro, Sergio, Miramontes-González, José P, Gómez-Huelgas, Ricardo
Tipo de recurso:	artículo
Fecha de publicación:	2022
País:	España
Institución:	Instituto de Salud Carlos III (ISCIII)
Repositorio:	Repisalud
Idioma:	inglés
OAI Identifier:	oai:repisalud.isciii.es:20.500.12105/18686
Acceso en línea:	http://hdl.handle.net/20.500.12105/18686
Access Level:	acceso abierto
Palabra clave:	health status heart failure obesity semaglutide type 2 diabetes Diabetes Mellitus, Type 2 Glucagon-Like Peptide-1 Receptor Glucagon-Like Peptides Heart Failure Humans Obesity Retrospective Studies

id	ES_2a0eeda1004f01bbc0c3c6eaec0f208d
oai_identifier_str	oai:repisalud.isciii.es:20.500.12105/18686
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.Pérez-Belmonte, Luis MSanz-Cánovas, JaimeGarcía de Lucas, María DRicci, MicheleAvilés-Bueno, BeatrizCobos-Palacios, LidiaPérez-Velasco, Miguel ALópez-Sampalo, AlmudenaBernal-López, M RosaJansen-Chaparro, SergioMiramontes-González, José PGómez-Huelgas, Ricardohealth statusheart failureobesitysemaglutidetype 2 diabetesDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 ReceptorGlucagon-Like PeptidesHeart FailureHumansObesityRetrospective StudiesThe impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure. In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months. A total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p In obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.20242024-02-2720222022-06-2420222022-06-24research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articlehttp://hdl.handle.net/20.500.12105/18686reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/186862026-06-12T12:43:37Z
dc.title.none.fl_str_mv	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
title	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
spellingShingle	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. Pérez-Belmonte, Luis M health status heart failure obesity semaglutide type 2 diabetes Diabetes Mellitus, Type 2 Glucagon-Like Peptide-1 Receptor Glucagon-Like Peptides Heart Failure Humans Obesity Retrospective Studies
title_short	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
title_full	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
title_fullStr	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
title_full_unstemmed	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
title_sort	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
dc.creator.none.fl_str_mv	Pérez-Belmonte, Luis M Sanz-Cánovas, Jaime García de Lucas, María D Ricci, Michele Avilés-Bueno, Beatriz Cobos-Palacios, Lidia Pérez-Velasco, Miguel A López-Sampalo, Almudena Bernal-López, M Rosa Jansen-Chaparro, Sergio Miramontes-González, José P Gómez-Huelgas, Ricardo
author	Pérez-Belmonte, Luis M
author_facet	Pérez-Belmonte, Luis M Sanz-Cánovas, Jaime García de Lucas, María D Ricci, Michele Avilés-Bueno, Beatriz Cobos-Palacios, Lidia Pérez-Velasco, Miguel A López-Sampalo, Almudena Bernal-López, M Rosa Jansen-Chaparro, Sergio Miramontes-González, José P Gómez-Huelgas, Ricardo
author_role	author
author2	Sanz-Cánovas, Jaime García de Lucas, María D Ricci, Michele Avilés-Bueno, Beatriz Cobos-Palacios, Lidia Pérez-Velasco, Miguel A López-Sampalo, Almudena Bernal-López, M Rosa Jansen-Chaparro, Sergio Miramontes-González, José P Gómez-Huelgas, Ricardo
author2_role	author author author author author author author author author author author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv	health status heart failure obesity semaglutide type 2 diabetes Diabetes Mellitus, Type 2 Glucagon-Like Peptide-1 Receptor Glucagon-Like Peptides Heart Failure Humans Obesity Retrospective Studies
topic	health status heart failure obesity semaglutide type 2 diabetes Diabetes Mellitus, Type 2 Glucagon-Like Peptide-1 Receptor Glucagon-Like Peptides Heart Failure Humans Obesity Retrospective Studies
description	The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure. In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months. A total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p In obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.
publishDate	2022
dc.date.none.fl_str_mv	2022 2022-06-24 2022 2022-06-24 2024 2024-02-27
dc.type.none.fl_str_mv	research article http://purl.org/coar/resource_type/c_2df8fbb1 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	http://hdl.handle.net/20.500.12105/18686
url	http://hdl.handle.net/20.500.12105/18686
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv	openAccess
dc.source.none.fl_str_mv	reponame:Repisalud instname:Instituto de Salud Carlos III (ISCIII)
instname_str	Instituto de Salud Carlos III (ISCIII)
reponame_str	Repisalud
collection	Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869405046171500544
score	15,811543

Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.

Similares en LA Referencia